SCHEMBL3866686

SCHEMBL3866686

COC(=O)c1cc(-c2ccc(SC)cc2)n(-c2ccc(C)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
PTGS2 P35354 1/20 0.55
PPP1CA P62136 1/20 0.55
CA9 Q16790 1/20 0.54
RPA1 P27694 3/20 0.50
MALT1 Q9UDY8 2/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
MAPK9 P45984 1/20 0.47
CHRNA7 P36544 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728116 0.91 SMPD1 (0.64) SMPD1SMN1; SMN2PTGS2PPP1CACA9
SCHEMBL3863714 0.89 RPA1 (0.60) SMN1; SMN2PTGS2RPA1MALT1NFKB1
SCHEMBL3863671 0.89 SMN1; SMN2 (0.69) SMPD1SMN1; SMN2PTGS2PPP1CARPA1
SCHEMBL3865146 0.89 PTGS2 (0.69) SMPD1SMN1; SMN2PTGS2PPP1CARPA1
SCHEMBL3873182 0.89 SMPD1 (0.58) SMPD1SMN1; SMN2PTGS2CA9RPA1
SCHEMBL861458 0.89 SMPD1 (0.55) SMPD1SMN1; SMN2PTGS2PPP1CACA9
SCHEMBL3876516 0.89 RPA1 (0.56) SMN1; SMN2PTGS2PPP1CARPA1MALT1
SCHEMBL9201539 0.88 CA9 (0.70) SMPD1SMN1; SMN2PTGS2PPP1CACA9
SCHEMBL861050 0.87 SMPD1 (0.53) SMPD1SMN1; SMN2PTGS2PPP1CACA9
SCHEMBL3870911 0.86 PTGS2 (0.54) SMN1; SMN2PTGS2MALT1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2009-01-01 US disclosed
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US disclosed
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-31 US disclosed
US-7087630-B2 Cyclooxygenase 2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-08 US disclosed
EP-1534683-A4 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-08-24 EP disclosed
EP-1534683-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-01 EP disclosed
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-03-18 US disclosed
WO-2004002409-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 SMPD1 1857/4885SMN1; SMN2 2470/4885PTGS2 1/4885
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 SMPD1 1857/4885SMN1; SMN2 2470/4885PTGS2 1/4885
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTGS2, PTGIS, PTGES2 SMPD1 1857/4885SMN1; SMN2 2470/4885PTGS2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.